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INTRODUCTION
Hepatic encephalopathy (HE) is a complex neuro-
psychiatric disorder associated with either hepatocellular 
insufficiency and/or the presence of porto-systemic shunts. It is 
thought to be induced by altered neurotransmission mediated 
by enhanced gamma-aminobutyric acid (GABA)-induced 
inhibitory tone.1-3 The use of benzodiazepines are generally 
avoided in patients with advanced chronic liver disease (CLD) 
because they enhance GABA-mediated neurotransmission. 
Zolpidem is a non-benzodiazepine hypnotic that selectively 
binds to the omega-1 GABA-benzodiazepine receptor 
complex. Although it theoretically has the same propensity to 
induce HE, its shorter half-life when compared to commonly 
prescribed benzodiazepines like diazepam, alprazolam and 
clonazepan, makes it a reasonable choice for subjects with 
CLD.4 
We report a patient with CLD with a rapidly induced 
grade IV HE attributed to zolpidem that was promptly 
reversed by flumazenil.
CASE REPORT
A 73-year-old female with a past history of Lewy body 
dementia, transient insomnia and arterial hypertension was 
admitted to our unit due to jaundice and ascitis dated one 
week before hospitalization. She was taking quetiapine 12 mg/
day and rivastigmine 12 mg/day for approximately six months. 
Physical examination disclosed involuntary movements of the 
upper limbs, temporal and spatial disorientation,  jaundice and 
moderate abdominal and ankle swelling. 
Laboratory data revealed AST 53 IU/L, ALT 65 
IU/L; alkaline phosphatase 187 IU/L; gammaglutamyl-
transpeptidase 117 IU/L; albumin 1.3 g/dL; bilirubin 3.48 
mg/dL and INR 1.75.
Screening for hepatitis B surface antigen (Enzyme 
Linked Immuno Sorbent Assay  -  ELISA, Abbott 
Laboratories, North Chicago, IL) and anti-hepatitis C 
virus (anti-HCV) antibodies (ELISA II, Ortho Diagnostic 
System, Raritan, New Jersey) yielded negative results, 
as did anti-smooth muscle, antinuclear, anti-liver kidney 
microsome type 1, anti-liver cytosol type 1 and anti-
mitochondrial antibodies. Other causes of CLD, such as 
hemochromatosis, alcoholic liver disease and alpha-1 
antitrypsin deficiency, were ruled out by history and the 
appropriate laboratory tests. Ultrasound examination 
revealed a shrunken liver with irregular surface, no 
biliary dilatation and a 3-cm hypoechoic nodule in 
the left lobe. Alpha-fetoprotein levels were 440 IU/L. 
Esophagogastroduodenoscopy showed small esophageal 
varices and moderate hypertensive gastropathy. 
In light of the diagnosis of cryptogenic cirrhosis 
complicated by hepatocellular carcinoma and ascitis, 
diuretics (spirolactone 100 mg/day and furosemide 40 mg/
day) were started. Eight days after admission, the patient 
developed clinical and laboratory signs of sepsis and acute 
deterioration of consciousness characterized by torpor that 
evolved to a Glasgow coma scale of 5.
She was transferred to the intensive care unit (ICU). 
Before tracheal intubation and empiric antibiotic coverage, 
the use of intravenous 1 mg flumazenil was attempted 
because the patient had received 10 mg zolpidem only 12 
hours before admission. Unexpectedly, the patient recovered 
to her basal state of consciousness 30 seconds after the bolus 
injection. After 14 days, the patient was discharged from the 
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hepatic insufficiency. She received supportive measures and 
died one week later in the nursing faculty. 
DISCUSSION
Zolpidem  tartrate  is  a  non-benzodiazepine 
imidazopiridine hypnotic with fast onset of action used 
to treat transient insomnia in doses averaging 5 to 10 mg 
per day. In contrast to benzodiazepines, which bind non-
selectively to all three omega gamma-aminobutyric acid-
benzodiazepine (GABA-benzodiazepine) receptor subtypes, 
zolpidem binds selectively to the omega-1 receptor, which 
could explain its lack of anxiolytic, muscle relaxant and 
anticonvulsant effects in its average therapeutic range.4 
Due to this mechanism, it is not unusually prescribed to 
patients with CLD. Its half-life is short in normal subjects 
but is significantly altered in old patients and subjects with 
CLD due to hepatic metabolism. These characteristics 
could explain the rapid onset of HE in this aged patient with 
advanced CLD, as well as her prompt recovery with the use 
of flumazenil, a benzodiazepines and zolpidem antagonist.4,5 
Sepsis and hypovolemia due to the use of diuretics could 
also be viewed as precipitants of HE in this patient, but the 
prompt recovery from HE with the use of flumazenil before 
fluid resuscitation and antibiotics argue against a major role 
for these triggers. It is worth mentioning that flumazenil has 
also been employed to treat HE unrelated to its hypnotic 
usage, but its role in this setting has not been validated in 
randomized controlled trials.6 However, it is more probable 
to assume that this patient’s immediate recovery was due 
to a flumazenil-induced antagonism of the  central nervous 
system effects caused by zolpidem because the patient had 
taken zolpidem only 12 hours before admission to the ICU 
due to HE.
In summary, HE could be precipitated by zolpidem in a 
similar manner to benzodiazepine hypnotics. Caution should 
be taken with the use of this drug in patients with advanced 
CLD because its half life could be severely prolonged with 
liver failure. It is notable that flumazenil is also an antagonist 
of non-benzodiazepine hypnotics, such as zolpidem, and 
could be efficaciously used to reverse HE induced by this 
class of drugs.
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